Krcméry V, Koza I, Mardiak J, Fuchsberger P, Spánik S, Trupl J, Horníková M, Kusenda Z, Sufliarsky J, Svec J
Department of Clinical Oncology, Postgraduate Medical School, National Cancer Institute, Bratislava, Czechoslovakia.
Chemotherapy. 1992;38(1):74-6. doi: 10.1159/000238944.
For the treatment of febrile episodes in granulocytopenic cancer patients, a combination of bactericidal and intravenously administered broad spectrum agents is recommended. An aminoglycoside plus a beta-lactame (piperacillin, azlocillin or IIIrd generation cephalosporins) are the drugs of first choice in an empiric approach. Because of frequent parenteral interventions (e.g. catheters, cannulations) in thrombopenic patients with multifactorial immunosuppression, we consider the application of once daily drugs, such as ceftriaxone, netilmicin or amikacin. For single dose treatment (1st day two applications), we used ceftriaxone in combination with netilmicin or amikacin as the first approach and retrospectively evaluated 47 patients for efficacy and safety.
对于粒细胞减少性癌症患者发热发作的治疗,推荐采用杀菌剂与静脉注射广谱药物联合使用的方法。氨基糖苷类药物加β-内酰胺类药物(哌拉西林、阿洛西林或第三代头孢菌素)是经验性治疗的首选药物。由于血小板减少且伴有多因素免疫抑制的患者常需进行肠外干预(如置管、插管),我们考虑使用每日一次给药的药物,如头孢曲松、奈替米星或阿米卡星。对于单剂量治疗(第1天给药两次),我们首先采用头孢曲松联合奈替米星或阿米卡星的治疗方法,并对47例患者的疗效和安全性进行了回顾性评估。